关涵月,王玉明

蒽环类药物是由微生物产生的具有抗肿瘤活性的化学物质，广泛应用于多种恶性肿瘤治疗，但其心脏毒性限制了其临床应用。心肌肌钙蛋白（cardiac troponin，cTn）作为心肌损伤的特异性标志物，在蒽环类药物心脏毒性的早期诊断、风险评估和预后监测中具有重要意义。本文综述了蒽环类药物心脏毒性的机制、肌钙蛋白的生物学特性及其在临床中的应用进展，探讨了肌钙蛋白检测优势及其在个体化治疗中的潜力，为未来研究提供方向。

化疗；蒽环类药物；心脏毒性；肌钙蛋白

[1] Han B,Zheng R,Zeng H,et al.Cancer incidence and mortality in China,2022[J].Journal of the National Cancer Center,2024,4(1):47-53. [2] Clerico A,Cardinale D M,Zaninotto M,et al.High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy[J].Clinical chemistry and laboratory medicine,2021,59(3):513-521. [3] Xiao H,Wang X,Li S,et al.Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction[J].2021. [4] Minotti G,Menna P,Salvatorelli E,et al.Anthracyclines:molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity[J].Pharmacological reviews,2004,56(2):185-229. [5] Singal PK,Iliskovic N.Doxorubicin-induced cardiomyopathy[J].American Journal of the Medical Sciences,1984,320(1):9-10. [6] Tadokoro T,Ikeda M,Ide T,et al.Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity[J].JCI Insight, 2020,5(9). [7] Alessandra M,Emilio H,Alessandra G.Mechanisms of Anthracycline-Induced Cardiotoxicity:Is Mitochondrial Dysfunction the Answer? [J].Frontiers in cardiovascular medicine,2020,7:35. [8] Wallace KB.Doxorubicin-Induced Cardiac Mitochondrionopathy[J].Pharmacology&Toxicology,2003,93(3):105-115. [9] Arola OJ,Saraste A,Pulkki K,et al.Acute Doxorubicin Cardiotoxicity Involves Cardiomyocyte Apoptosis[J].Cancer Research, 2000, 60(7):1789-1792. [10] Wang JC.Cellular roles of DNA topoisomerases:a molecular perspective.[J].Nature Reviews Molecular Cell Biology, 2002,3(6):430-440. [11] Zhang S,Liu X,Bawa-Khalfe T,et al.Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J].Nature Medicine, 2012,18(11):1639-1642. [12] Finkel,Toren.Cell biology:a clean energy programme.[J].Nature,2006,444(7116):151-152. [13] Lyu YL,Kerrigan JE,Lin C P,et al.Topoisomerase IIβ–Mediated DNA Double-Strand Breaks:Implications in Doxorubicin Cardioto- xicity and Prevention by Dexrazoxane[J].Cancer Research,2007,67(18):8839-8846. [14] Zhang H,Ding X,Qiu Y,et al.Preventive effect of imperatorin against doxorubicin-induced cardiotoxicity through suppression of NLRP3 inflammasome activation[J].J Nat Med,2025,79(1):95-106. [15] Tayal R,Mannan A,Singh S,et al.Unveiling the Complexities:Exploring Mechanisms of Anthracyclineinduced Cardiotoxicity[J].Curr Cardiol Rev,2025,21(2):42-77. [16] Li Y,Lin R,Peng X,et al.The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity:From Bench to Bedside[J].Oxid Med Cell Longev,2022,2022:3659278. [17] Sun X,Meng H,Xiao J,et al.Pretreatment of 3-MA prevents doxorubicin-induced cardiotoxicity through inhibition of autophagy initiation[J].Toxicology,2023,490:153512. [18] Porcari A,Baggio C,Fabris E,et al.Endomyocardial biopsy in the clinical context:current indications and challenging scenarios[J].Heart Fail Rev,2023,28(1):123-135. [19] Ibrahim EH,Chaudhary L,Cheng YC,et al.Cardiac MRI for differentiating chemotherapy-induced cardiotoxicity in sarcoma and breast cancer[J].Radiol Oncol,2025,59(1):79-90. [20] Hu Y,Ma P,Chen L,et al.Multi-parameter cardiac magnetic resonance imaging detects anthracycline-induced cardiotoxicity in rabbits model[J].Heliyon,2023,9(11):e21845. [21] Totzeck M,Schuler M,Stuschke M,et al.Cardio-oncology-strategies for management of cancer-therapy related cardiovascular disease[J]. International Journal of Cardiology,2019. [22] Prasad K,Yadav BS,Zohmangaihi D,et al.Evaluation of anthracycline-induced cardiotoxicity using cardiac biomarkers:A prospective study[J].Indian J Cancer,2024. [23] 中国医师协会心力衰竭专业委员会，国家心血管病专家委员会心力衰竭专业委员会，中华心力衰竭和心肌病杂志编辑委员会.心力衰竭生物标志物临床应用中国专家共识[J].中华心力衰竭和心肌病杂志,2022(03):175-192. [24] Michel L,Mincu RI,Mahabadi AA,et al.Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients:a meta-analysis[J].Eur J Heart Fail,2020,22(2):350-361. [25] Wright CX,Wright DS,Hu JR,et al.High-Sensitivity Troponin:Finding a Meaningful Delta[J].J Cardiovasc Dev Dis,2024,11(10). [26] Aakre KM,Saenger AK,Body R,et al.Analytical Considerations in Deriving 99th Percentile Upper Reference Limits for High- Sensitivity Cardiac Troponin Assays:Educational Recommendations from the IFCC Committee on Clinical Application of Cardiac Bio- Markers[J].Clin Chem,2022,68(8):1022-1030. [27] Cardinale D,Sandri M T,Martinoni A,et al.Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.[J].Journal of the American College of Cardiology,2000,36(2):517-522. [28] Gulati G,Heck SL,Røsjø,H,et al..Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients:Results From the PRADA(Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy)Study[J].J Am Heart Assoc,2017;6(11):e6513. [29] Fornaro A,Olivotto I,Rigacci L,et al.Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy:a single centre experience[J].European journal of heart failure,2018,20(5):898-906. [30] Kariuki N,Kimani E,Jowi C,et al.Early myocardial injury in children on doxorubicin for cancer chemotherapy:a cross-sectional study in a tertiary referral centre in Kenya[J].BMC cardiovascular disorders,24(1):260. [31] Armenian SH,Hudson MM,Mulder RL,et al.Recommendations for cardiomyopathy surveillance for survivors of childhood cancer:a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group[J].The Lancet Oncology, 2015, 16(3):e123-e136. [32] Rao VU,Reeves DJ,Chugh AR,et al.Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents:JACC State-of- the-Art Review[J].Journal of the American College of Cardiology,2021,77(21):2693-2716. [33] Cardinale DM.Role of Cardiac Biomarkers in Cancer Patients[J].Cancers,2021,13. [34] Rushton M,Johnson C,Dent S.Trastuzumab-induced cardiotoxicity:testing a clinical risk score in a real-world cardio-oncology population[J].Current Oncology,2017,24(3):176. [35] Sawaya H,Sebag IA,Plana JC,et al.Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines,Taxanes,and Trastuzumab[J].Circulation Cardiovascular Imaging,2012,5(5):596. [36] Avila MS,Ayub-Ferreira SM,Rogerio D B W J,et al.Carvedilol for Prevention of Chemotherapy Related Cardiotoxicity:The CECCY Trial[J].Journal of the American College of Cardiology,2018;71(20):2281-2290. [37] Cardinale DM.Role of Cardiac Biomarkers in Cancer Patients[J].Cancers,2021,13.. [38] Celutkiene J,Pudil R,Lopez-Fernandez T,et al.Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies:a position statement on behalf of the Heart Failure Association(HFA),the European Association of Cardiovascular Imaging(EACVI)and the Cardio-Oncology Council of the European Society of Cardiology(ESC)[J].Eur J Heart Fail,2020,22(9):1504-1524.

点击下载PDF